Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14658MR)

This product GTTS-WQ14658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14658MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2325MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ4790MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ8719MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ10308MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ10460MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ10136MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ7082MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1835MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW